- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04050254
tDCS Combined With Therapeutic Exercise in Fibromyalgia Patients
Effects of Transcranial Direct Current Stimulation Combined With Therapeutic Exercise in Fibromyalgia Patients. A Triple-blinded, Randomized, Placebo-controlled Trial
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Fibromyalgia is one of the rheumatic diseases with the greatest impact on the quality of life, whose etiology and pathophysiology is not yet fully demonstrated. Perhaps this is why its therapeutic approach is refractory to current treatments.
Based on the theory that fibromyalgia is characterized by a sensitization at the level of the central nervous system that leads to an increase in the perception of pain, any therapeutic approach aimed at modulating the central nervous system may be beneficial. Electrical stimulation with transcranial direct current (tDCS) is among these techniques.
In the same way, therapeutic exercise has shown to have, like the tDCS, a beneficial effect on pain in different chronic pathologies.
The present study aims to investigate the effect on pain of a combination therapy of tDCS and therapeutic exercise in patients with fibromyalgia.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Toledo
-
Talavera De La Reina, Toledo, Espagne, 45600
- Hospital General Nuestra Señora del Prado
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age between 18 and 65 years.
- Fulfilled the 2010 American Colleague of Rheumatology criteria for fibromyalgia.
- Normal pain intensity of 4 or more points on a visual analog scale.
- Able to participated in a therapeutic exercise program.
- Understanding of spoken and written Spanish.
Exclusion Criteria:
- Pregnancy or breastfeeding.
- Metallic implants in the head.
- Tumor, trauma or surgery in the brain.
- Epilepsy or stroke.
- History of substance abuse in the last 6 months.
- Use of carbamazepine in the last 6 months.
- Severe depression (Beck Depression Index II of 29 or more).
- Diagnosed psychiatric pathology.
- Rheumatic pathology not medically controlled.
- Coexisting autoimmune pathology.
- Chronic inflammatory disease (rheumatoid arthritis, erythematosus systemic lupus, inflammatory bowel disease).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Aucune intervention: Contrôle
Aucun traitement.
|
|
Expérimental: Real tDCS + exercise
Transcranial direct current stimulation combined with therapeutic exercise
|
Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days.
The program will include exercises and will last 30-45 minutes.
|
Comparateur factice: Sham tDCS + exercise
Sham transcranial direct current stimulation combined with therapeutic exercise
|
The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days.
The program will include exercises and will last 30-45 minutes.
Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.
Sham tDCS will be applied for the same time than real tDCS.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in referred pain area after suprathreshold pressure stimulation from baseline to post-treatment
Délai: Baseline; immediately after intervention; 1-month after intervention
|
A pressure algometer (Force Ten™, Wagner Instruments, USA) will be used. It will be performed on the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) at a constant suprathreshold pressure (20% above the pressure pain threshold) for 60 seconds. After the stimulation, the subject should draw the induced pain area on a digital bodychart using the Navigate Pain application (Navigate Pain, Aalborg University, Denmark). |
Baseline; immediately after intervention; 1-month after intervention
|
Change in pain intensity from baseline to post-treatment
Délai: Baseline; immediately after intervention; 1-month after intervention
|
It will be measured with a visual analog scale (VAS) of 100 millimeters in length.
The subject has to indicate the level of pain he feels, being 0 the absence of pain and 100 the maximum imaginable
|
Baseline; immediately after intervention; 1-month after intervention
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
La fibromyalgie impacte la qualité de vie
Délai: Base de référence ; immédiatement après l'intervention ; 1 mois après l'intervention
|
Il sera mesuré avec la version adaptée à l'espagnol du Fibromyalgia Impact Questionnaire (FIQ).
L'échelle va de 0 à 100.
Des valeurs plus élevées représentent un résultat moins bon.
|
Base de référence ; immédiatement après l'intervention ; 1 mois après l'intervention
|
Anxiety
Délai: Baseline; immediately after intervention; 1-month after intervention
|
The version adapted to Spanish from the State Scale (STAI-ES) of the State-Trait Anxiety Inventory (STAI) will be used.
The scale ranges from 0 to 60. Higher values represent a worse result.
|
Baseline; immediately after intervention; 1-month after intervention
|
Pain catastrophizing
Délai: Baseline; immediately after intervention; 1-month after intervention
|
The Spanish version of the Pain Catastrophizing Scale (PCS) will be used.
The scale ranges from 0 to 52.
Higher values represent a worse result.
|
Baseline; immediately after intervention; 1-month after intervention
|
Depression
Délai: Baseline; immediately after intervention; 1-month after intervention
|
The adaptation to the Spanish of Beck Depression Inventory II will be used.
The scale ranges from 0 to 63.
Higher values represent a worse result.
|
Baseline; immediately after intervention; 1-month after intervention
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Blinding
Délai: Immediately after intervention
|
Blinding of subjects and researchers will be assessed using the James Index.
|
Immediately after intervention
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- tDCS+ET-Fibromyalgia
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Real tDCS
-
Hospital de Clinicas de Porto AlegreActif, ne recrute pas
-
Arizona State UniversityUniversidad Autonoma de Nuevo Leon; Instituto Nacional Psiquiatrico de México... et autres collaborateursComplété
-
Penn State UniversityComplétéProblème de toxicomanieÉtats-Unis
-
The Hong Kong Polytechnic UniversityThe University of Hong Kong; University of Magdeburg; University of WaterlooRecrutement
-
University of Southern CaliforniaComplété
-
Children's Hospital Medical Center, CincinnatiRésilié
-
Real Prevention, LLCRetiré
-
Federal University of ParaíbaUniversidade Federal do Rio Grande do NorteInconnueAccident vasculaire cérébral | Déficience cognitive | Infarctus cérébralBrésil
-
Dr. Zahra Kazem-MoussaviComplétéLa maladie d'AlzheimerCanada
-
Medical University of South CarolinaComplétéAccident vasculaire cérébralÉtats-Unis